Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM3 | Q86V86 | 1/20 | 0.74 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 4/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1520694 | 0.87 | PIM3 (0.74) | PIM3PIM2KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL1043176 | 0.85 | PIM3 (0.72) | PIM3PIM2KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL20683254 | 0.83 | PIM3 (0.68) | PIM3PIM2KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL13614233 | 0.79 | PIM3 (0.63) | PIM3PIM2KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL20239408 | 0.78 | PIM3 (0.62) | PIM3PIM2KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL31130245 | 0.76 | PIM3 (0.59) | PIM3PIM2KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL13283350 | 0.74 | PIM3 (0.57) | PIM3PIM2KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL3083301 | 0.71 | PIM3 (0.54) | PIM3PIM2KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL12733934 | 0.69 | PIM3 (0.51) | PIM3PIM2KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL12806939 | 0.69 | PIM3 (0.51) | PIM3PIM2KDM4EALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260055062-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | Vettore, LLC | 2026-02-26 | — | — | US | disclosed |
| US-12492171-B2 | Heterocyclic inhibitors of MCT4 | Vettore, LLC (US) | 2025-12-09 | — | — | US | disclosed |
| EP-4442318-A2 | HETEROCYCLIC INHIBITORS OF MCT4 | Vettore, LLC (US) | 2024-10-09 | — | — | EP | disclosed |
| CN-110114351-B | Heterocyclic inhibitors of MCT4 | 维托尔股份有限公司 | 2022-09-20 | — | — | CN | disclosed |
| US-20220251047-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | Vettore, LLC | 2022-08-11 | — | — | US | disclosed |
| US-11292767-B2 | Heterocyclic inhibitors of MCT4 | Vettore, LLC (US) | 2022-04-05 | — | — | US | disclosed |
| EP-3551625-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | Vettore, LLC (US) | 2019-10-16 | — | — | EP | disclosed |
| US-20190112275-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | Vettore, LLC | 2019-04-18 | — | — | US | disclosed |
| US-20190112275-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | Vettore, LLC | 2019-04-18 | — | — | US | disclosed |
| WO-2018111904-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | Vettore, LLC (US) | 2018-06-21 | — | — | WO | disclosed |
| WO-2018111904-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | Vettore, LLC (US) | 2018-06-21 | — | — | WO | disclosed |
| US-20180162822-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | Vettore, LLC | 2018-06-14 | — | — | US | disclosed |
| US-20180162822-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | Vettore, LLC | 2018-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12492171-B2 | Heterocyclic inhibitors of MCT4 | SLC16A3, SLC16A1, MCTS1 | PIM3 2997/4885PIM2 3208/4885KDM4E 2829/4885 |
| US-11292767-B2 | Heterocyclic inhibitors of MCT4 | SLC16A3, SLC16A1, MCTS1 | PIM3 2997/4885PIM2 3208/4885KDM4E 2829/4885 |
| US-20190112275-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | SLC16A3, SLC16A1, MCTS1 | PIM3 2997/4885PIM2 3208/4885KDM4E 2829/4885 |
| US-20220251047-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | SLC16A3, SLC16A1, MCTS1 | PIM3 2997/4885PIM2 3208/4885KDM4E 2829/4885 |
| US-20180162822-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | SLC16A3, SLC16A1, MCTS1 | PIM3 2997/4885PIM2 3208/4885KDM4E 2829/4885 |
| US-20260055062-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | SLC16A1, SLC16A3, SLC16A7 | PIM3 1176/4885PIM2 860/4885KDM4E 473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.